Drug Profile


Alternative Names: Antiplatelet thrombolysin for injection - Lee's Pharmaceutical; Declotana; ZK 001

Latest Information Update: 17 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lees Pharmaceutical Holdings
  • Class Antiplatelets; Ischaemic heart disorder therapies; Peptides; Snake venoms
  • Mechanism of Action Adhesion receptor antagonists; Platelet glycoprotein GPIb-IX complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombotic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myocardial infarction

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 24 Mar 2016 Anfibatide receives Orphan Drug status for Thrombotic thrombocytopenic purpura in USA
  • 10 Dec 2015 Phase-II clinical trials in Myocardial infarction in China (IV) (Company pipeline, Dec 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top